Lupus nephritis is the most common severe manifestation of the autoimmune disease systemic lupus erythematosus. Although conventional immunosuppressive therapy can increase survival, this approach is associated with considerable adverse effects. In this Review, Gregersen and Jayne discuss the available and future approaches to deplete B-cell populations and the current evidence for the therapeutic use of B cell depletion therapies in lupus nephritis, derived from case studies and clinical trials.
- Jon W. Gregersen
- David R. W. Jayne